Molecule that Provides Cellular Energy Found Key to Aggressive Thyroid Cancer

In an online issue of The Journal of Clinical Endocrinology and Metabolism, they identify Stearoyl-CoA desaturase 1 (SCD1) as an oncogenic enzyme that when inhibited and paired with another targeted drug effectively shuts down ATC cell growth and induces cell death.

Investigators think that ATC relies on SCD1 to provide the fuel the cancer cells need to rapidly duplicate. The molecule provides this energy by promoting the cancer cell’s ability to generate certain fatty acids that are important for several biological processes such as cell division, survival, drug resistance and migration.

“We now have some hope for treatment of this cancer, which is arguably the most lethal solid tumor known to medicine,” says John Copland, Ph.D., a cancer biologist and the study’s senior author. “Although ATC is rare — accounting for only 1 to 2 percent of thyroid cancers, it is responsible for up to 39 percent of all thyroid cancer-related deaths.”

“Currently, there are no therapies for ATC that lead to prolonged survival, but I think combining an SCD1 inhibitor with a cocktail of other agents, all of which have dramatically different targets and approaches, may work,” says co-author Robert Smallridge, M.D., an endocrinologist who treats thyroid cancer.

The Mayo researchers have already developed SCD1 inhibitors and are testing the agents in different tumor models.

Cells normally take the fatty acids they need from the bloodstream, instead of making them internally, says lead author Christina von Roemeling, a graduate student and cancer researcher. “But we have found this very unique switch in tumors that makes them very dependent on this method of fatty acid synthesis,” she says.

“Given the work we have done in the past several years, it is becoming really clear to us that fatty acid metabolism is quite possibly a crutch used by many cancers,” von Roemeling says. “An SCD1 inhibitor might be a therapeutic target that is multipotent for several cancers — not just a one-hit wonder in a single cancer but very useful as a generic therapy.”

“We have seen activity of SCD1 in a number of cancer cell lines — everything from melanoma to ovarian and breast cancer to prostate and pancreatic cancer,” says Dr. Copland.

“We now have a new area of cancer therapy to explore that has not been looked at yet in anaplastic thyroid cancer,” adds Dr. Smallridge.

Other study co-authors include Laura Marlow, Angela Crist, James Miller and Han Tun, M.D., from Mayo Clinic; and Anthony Pinkerton from the Conrad Prebys Center for Chemical Genomics at Sanford-Burnham Medical Research Institute in La Jolla, California.

This work was funded in part from National Institutes of Health / National Cancer Institute grant R01CA136665; Florida Department of Health Bankhead-Coley Cancer Research Program (FL09B202, FL3BF01, JAC); Mr. and Mrs. Ompal Chauhan Research Fund; Scheidel Foundation; Fraternal Order of Eagles Florida State Auxiliary; a grant for rare cancers from Dr. Ellis and Dona Brunton; Mayo Sanford-Burnham Medical Research Institute Collaborative Drug Discovery Program; a gift from Alfred D. and Audrey M. Petersen; the Francis and Miranda Childress Foundation Fund for Cancer Research; John A. and Bette B. Klacsmann Fund for Cancer Research at Mayo Clinic in Florida; and the Betty G. Castigliano Fund in Cancer Research Honoring S. Gordon Castigliano, M.D. cancer research at Mayo Clinic in Jacksonville, Florida.

###

About Mayo ClinicMayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit mayoclinic.com or newsnetwork.mayoclinic.org.

MEDIA CONTACT: Kevin Punsky, Mayo Clinic Public Affairs, 904-953-0746. Email: [email protected]